In Brief: Trylon's Pap Plus Speculoscopy
This article was originally published in The Gray Sheet
Executive Summary
Trylon's Pap Plus Speculoscopy: Visual cervical screening exam using the firm's Speculite disposable chemiluminescent illuminator receives FDA 510(k) clearance for the claim that it increases the sensitivity of screening, when compared with Pap smear alone, from 40% to 90%, according to the Torrance, California-based firm. Specificity, however, decreases from 95% to 80%. The firm also will provide participating Planned Parenthood clinics with the exam at no additional cost for low income, uninsured women who receive their cervical screening at the clinics...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.